Top

Diabetologia

Published in:

01-08-2003 | Article

LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats

Authors: J. L. Figarola, S. Scott, S. Loera, C. Tessler, P. Chu, L. Weiss, J. Hardy, S. Rahbar, MD PhD

Published in: Diabetologia | Issue 8/2003

Abstract

Aims/hypothesis

Advanced glycation and lipoxidation endproducts have been implicated in the pathogenesis of diabetic complications, including diabetic nephropathy. LR-90, a new advanced glycation endproduct inhibitor, was investigated for its effects on the development of renal disease in diabetic rats.

Methods

Diabetic animals were randomly allocated into groups receiving LR-90 or vehicle (untreated). Age- and weight-matched non-diabetic rats were studied concurrently. Body weight, plasma glucose, glycated haemoglobin, urinary albumin and creatine excretions were measured serially. Kidney histopathology, AGE accumulation in cells and tissues, protein oxidation, were also examined. In vitro assays were used to assess the possible mechanism of action of LR-90.

Results

LR-90 inhibited the increase in albumin and creatinine concentrations, and concentrations of circulating AGE in diabetic rats without any effect on glycaemic control. LR-90 treated-rats also showed higher body weights than untreated diabetic rats. LR-90 prevented glomerulosclerosis, tubular degeneration and collagen deposition in the kidney. AGE-induced cross-linking and fluorescence of tail collagen were reduced by LR-90 treatment. LR-90 also decreased AGE accumulation in kidney glomeruli and nitrotyrosine deposition in the renal cortex. In vitro, LR-90 was capable of reacting with reactive carbonyl compounds and was a more potent metal chelator than pyridoxamine and aminoguanidine.

Conclusion/interpretation

LR-90 reduces in vivo AGE accumulation, AGE-protein cross-linking and protein oxidation, and could be beneficial in preventing the progression of diabetic nephropathy. The AGE inhibitory and therapeutic effects of LR-90 could be attributed, at least in part, to its ability to react with reactive carbonyl species and/or potent metal chelating activity that inhibits glycoxidative-AGE formation.

Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23: 1–34PubMed

Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Ann Rev Med 46:223–234CrossRefPubMed

Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44: 129–146PubMed

Schleicher ED, Bierhaus A, Haring HU, Nawroth, Lehmann R (2001) Chemistry and pathobiology of advanced glycation end products. Contrib Nephrol 131:1–9PubMed

Vlassara H, Palace MR (2002) Diabetes and advanced glycation endproducts. J Intern Med 251:87–101PubMed

Miyata T, Kurokawa K, De Strihou CVY (2000) Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism

Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1–9PubMed

Wolff SP, Bascal ZA, Hunt JV (1989) Autoxidative glycosylation: free radicals and glycation theory. Prog Clin Biol Res 304:259–275PubMed

Wolff SP, Jiang, ZY, Hunt JV (1991) Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol and Med 10:339–352CrossRef

10.

Loske C, Gerdemann A, Schepl et al. (2000) Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 267:4171–4178CrossRefPubMed

11.

Scivittaro V, Ganz MB, Weiss MF (2000) AGEs induce oxidative stress and activate protein kinase C-beta (II) in neonatal mesangial cells. Am J Physiol Renal Physiol 278:F676–F683PubMed

12.

Suzuki D, Miyata T, Saotome N et al. (1999) Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10:822–832PubMed

13.

Miyata T, Wada Y, Cai Z et al. (1997). Implications of an increased oxidative stress in the formation of advanced glycation endproducts in patients with end stage renal failure. Kidney Int 51:1170–1181PubMed

14.

Friedman EA (1999) Advanced glycation end-prodcuts in diabetic nephropathy. Nephron Dial Transplant 14 [Suppl. 3]:1–9

15.

Mogensen CE (1999) Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 42:263–285CrossRefPubMed

16.

Lehmann R, Schleicher ED (2000) Molecular mechanism of diabetic nephropathy. Clin Chim Acta 297:135–144CrossRefPubMed

17.

Yamamoto Y, Kato I, Doi T et al. (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261–268CrossRefPubMed

18.

Makita Z, Radoff S, Rayfield EJ et al. (1991) Advanced glycation endproducts in patients with diabetic nephropathy. N Engl J Med 325:836–842PubMed

19.

Vlassara H, Fuh H, Makita Z, Li YM, Steffes M (1994) Advanced glycation end-products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704–11708PubMed

20.

Bendayan M (1998) Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 54:438–447PubMed

21.

Imai N, Nishi S, Suzuki Y et al. (1997) Histological localization of advanced glycosylation end products in the progression of diabetic nephropathy. Nephron 76:153–160PubMed

22.

Horie K, Miyata T, Maeda K et al. (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100:2995–3004PubMed

23.

Heidland A, Sebekova K, Schinzel R (2001) Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38 [4 Suppl 1]:S100–S1006

24.

Aronson D (2002) Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses 59:297–301CrossRefPubMed

25.

Bailey AJ, Paul RG, Knott L (1998) Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 106:1–56CrossRefPubMed

26.

Dukic-Stefanovic S, Schinzel R, Riederer P, Munich G (2001) AGEs in the brain: AGE-inhibitors as neuroprotective and anti-dementia drugs. Biogerontology 2:19–34CrossRefPubMed

27.

Rahbar S, Figarola JL (2002) Inhibitors and breakers of advanced glycation endproducts. Curr Med Chem—Immunol Endocrin Metabol 2:174–186

28.

Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629–1632PubMed

29.

Hammes HP, Martin S, Federin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555–11558PubMed

30.

Bonnefont-Rousselot D (2001) Antioxidant and anti-AGE therapeutics: evaluation and perspectives. J Soc Biol 195:391–398PubMed

31.

Booth AA, Khalifah RG, Hudson BG (1996) Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun. 220:113–119

32.

Suzuki YJ, Tsuchiya M, Packer L (1992) Lipoate prevents glucose-induced protein modifications. Free Radic Res Commun 173:211–217

33.

Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW (2000) Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions: mechanism of action of pyridoxamine. J Biol Chem 275:21177–21184CrossRefPubMed

34.

Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N (1999) Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 58:1765–1773CrossRefPubMed

35.

Nakamura S, Makita Z, Ishikawa S et al. (1997) Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:895–899PubMed

36.

Forbes JM, Soulis T, Thallas V et al. (2001) Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44:108–114CrossRefPubMed

37.

Ninomiya T, Tsutsumi S, Kawaguchi M (2001) EF655, a novel AGE production inhibitor, prevents progression of diabetic nephrophaty in STZ-induced diabetic rats. American Diabetes Association 61st Scientific Session, Philadelphia, PA (Abstract No 724-P)

38.

Vasan S, Zhang X, Zhang, XI et al.(1996) An agent cleaving glucose-derived protein cross-links in vitro and in vivo. Nature 382:275–278PubMed

39.

Vaitkevicius PV, Lane M, Spurgeon H et al. (2000) A cross-link breaker has sustained effects on arterial and ventricular properties of older rhesus monkey. Proc Natl Acad Sci USA 98:1171–1175CrossRef

40.

Rahbar S, Yernini K, Scott S, Gonzales N, Lalezari I (1999) Novel inhibitors of glycation endproducts. Biochem Biophys Res Commun 262:651–656CrossRefPubMed

41.

Rahbar S, Yerneni K, Scott S, Gonzales N, Lalezari I (2000) Novel inhibitors of advanced glycation endproducts (Part II). Mol Cell Biol Res Comm 3:360–366CrossRef

42.

Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G (1991). Retardation of aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozotocin-induced diabetic rats. Diabetes 40:1328–1334PubMed

43.

Degenhardt TP, Alderson NL, Arrington DD et al. (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in streptozotocin-diabetic rats. Kidney Int 61:939–950CrossRefPubMed

44.

Al-Abed Y, Kapurniotu A, Bucala R (1999) Advanced glycation end products: detection and reversal. Methods Enzymol 309:152–172PubMed

45.

Kochakian M, Manjula BN, Egan JJ (1996) Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes 45:1694–1700PubMed

46.

Stefek M, Gajdosik A, Gajdosikova A, Krizanova L (2000) p-Dimethyl aminobenzaldehyde-reactive substances in tail tendon collagen of streptozotocin-diabetic rats: temporal relation to biomechanical properties and advanced glycation endproduct (AGE)-related fluorescence. Biochim Biophys Acta 1502:398–404CrossRefPubMed

47.

Creemers LB, Jansen DC, van Veen-Reurings A, van den Bos T, Everts V (1997) Microassay for the assessment of low levels of hydroxyproline. Biotechniques 22:656–658PubMed

48.

Verzijl N, DeGroot J, Oldehinkel E et al. (2000) Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 350:381–38PubMed

49.

Wilkinson-Berka JL, Kelly DJ, Koerner SM et al. (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) 27 rat. Diabetes 51:3283–3289PubMed

50.

Forbes JM, Cooper ME, Thallas V et al. (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274–3282PubMed

51.

Price DL, Rhett PM, Thorpe SR, Baynes JW (2001) Chelating activity of advanced glycation end-products inhibitors. J Biol Chem 276:48967–48972CrossRefPubMed

52.

Voziyan PA, Metz TO, Baynes JW, Hudson BG (2002) A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277:3397–3403CrossRefPubMed

53.

Lalezari I, Rahbar S, Lalezari P, Fermi G, Perutz MF (1988) LR16, a compound with potent effects on the oxygen affinity of hemoglobin, on blood cholesterol, and on low density lipoprotein. Proc Natl Acad Sci USA 85:6117–6121PubMed

54.

Lyons T, Jenkins AJ (1997) Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus: a 'carbonyl stress' hypothesis. Diabetes Rev 5:365–391

55.

Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109–116CrossRefPubMed

56.

Miyata T, Saito A, Kurokawa K, van Ypersele de Strihou C (2001) Advanced glycation and lipoxidation end products: reactive carbonyl compounds-related uraemic toxicity. Nephrol Dial Transplant 16 [Suppl 4]:8–11

57.

Lo TW, Selwood T, Thornalley PJ (1994) The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharmacol 48:1865–70PubMed

58.

Thornalley PJ, Yurek-George A, Argirov OK (2000) Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 60:55–65CrossRefPubMed

59.

Nagaraj RH, Sarkay P, Mally A, Biemel KM, Lederer MO, Padayatti PS (2002) Effects of pyridoxamine on chemical modifications of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine with metholglyoxal. Arch Biochem Biophys 402:110–119CrossRefPubMed

60.

Kislinger T, Fu C, Huber B et al. (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749PubMed

61.

Morcos M, Sayed AA, Bierhaus A et al. (2002) Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51:3532–3544PubMed

62.

Boulanger E, Wautier MP, Wautier JL et al. (2002) AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 61:148–156CrossRefPubMed

63.

Basta G, Lazzerini G, Massaro M et al. (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105:816–822CrossRefPubMed

64.

Thuraisingham RC, Nott CA, Dodd SM, Yaqoob MM (2000) Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 57:968–972CrossRef

65.

Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:C1424–C1437PubMed

66.

Reiter CD, Teng RJ, Beckman JS (2000) Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J Biol Chem 275:32460–32466CrossRefPubMed

67.

Sakurai T, Tsuchiya S (1988) Superoxide production from nonenzymatically glycated protein. FEBS Lett 236:406–410CrossRefPubMed

68.

Yim HS, Kang SO, Hah YC, Chock PB, Yim MB (1995) Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. J Biol Chem 270:28228–28233CrossRefPubMed

69.

Ortwerth BJ, James H, Simpson G, Linetsky M (1998) The generation of superoxide anions in glycation reactions with sugars, osones, and 3-deoxyosones. Biochem Biophys Res Commun 245:161–165CrossRefPubMed

70.

Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685–E694PubMed

71.

Sajithal GB, Pandarinathan C, Chadrakasan G (1999) An in vitro study on the role of metal catalyzed oxidation in glycation and cross-linking of collagen. Mol Cell Biol 194:257–263CrossRef

72.

Qian M, Liu M, Eaton JW (1998) Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 250:385–389CrossRefPubMed

73.

Saxena AK, Saxena P, Wu X, Obrenovich M, Weiss MF, Monnier VM (1999) Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun 260:332–338CrossRefPubMed

74.

Yim MB, Yim HS, Lee C, Kang SO, Chock PB (2001) Protein glycation: creation of catalytic sites for free radical generation. Ann NY Acad Sci 928:48–53PubMed

75.

Litchfield JE, Thorpe SR, Baynes JW (1999) Oxygen is not required for the browning and cross-linking of protein by pentoses: relevance to Maillard reactions in vivo. Int J Biochem Cell Biol 1999 31:1297–1305CrossRef

76.

Glomb MA, Monnier VM (1995) Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270:10017–10026PubMed

77.

Khalifah RG, Chen Y, Price DL, Booth AA (2002) Mechanism of inhibition of advanced glycation endproducts by Pyridorin™, a novel therapeutic for diabetic complications. Diabetologia 45 [Suppl 2]:A1222 (Abstract)

Title: LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats
Authors: J. L. Figarola
S. Scott
S. Loera
C. Tessler
P. Chu
L. Weiss
J. Hardy
S. Rahbar, MD PhD
Publication date: 01-08-2003
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 8/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-003-1162-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats

Abstract

Aims/hypothesis

Methods

Results

Conclusion/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusion/interpretation

Please log in to get access to this content

Other articles of this Issue 8/2003

Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents

Factors affecting diabetes knowledge in Type 2 diabetic veterans

Insulin granule dynamics in pancreatic beta cells

Voltage-dependent K+ channels in pancreatic beta cells: Role, regulation and potential as therapeutic targets

Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension

The influence of the ACE (I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page